Filing Flows › Comparisons › INCY vs CRL
Incyte vs Charles River Laboratories International: INCY and CRL compared
Incyte is the larger company: $1.6B of revenue in its latest quarter (Q3 2026) against $983M for Charles River Laboratories International (Q3 2026). Incyte is growing faster (+14% against -2% a year earlier). Charles River Laboratories International is more profitable, with an operating margin of 20.6% against -45.5%.
Where the money goes: INCY and CRL
Incyte (INCY) · Q3 2026
Incyte, Q3 2026: revenue $1.6B (+14% year over year), operating margin -45.5%, net loss $785M, operating cash flow −$675M. The chart follows the revenue to costs, profit and cash.
Charles River Laboratories International (CRL) · Q3 2026
Charles River Laboratories International, Q3 2026: revenue $983M (-2% year over year), operating margin 20.6%, net earnings $333M, operating cash flow $254M. The chart follows the revenue to costs, profit and cash.
| Incyte (INCY) | Charles River Laboratories International (CRL) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $1.6B | $983M |
| Revenue growth, Y/Y | +14% | -2% |
| Operating margin | -45.5% | 20.6% |
| Net earnings | −$785M | $333M |
| Net margin | -50.4% | 33.9% |
| Operating cash flow | −$675M | $254M |
| Free cash flow | — | $207M |
| Market value | $24.2B | $16.4B |
| P/E | 63.5× | — |
| Analysts’ mean target | $131.50 | $333.53 |
Where the revenue comes from
Incyte
- Net sales: $1.3B (85%)
- NIKTIMVO: $67.4M (4%)
- ZYNYZ: $58.3M (4%)
- OLUMIANT: $39.1M (3%)
Charles River Laboratories International
- DSA: $596M (61%)
- RMS: $208M (21%)
- Manufacturing: $179M (18%)
Questions
Which is bigger, Incyte or Charles River Laboratories International?
Incyte is the larger company: $1.6B of revenue in its latest quarter (Q3 2026) against $983M for Charles River Laboratories International (Q3 2026).
Is Incyte or Charles River Laboratories International growing faster?
Incyte is growing faster (+14% against -2% a year earlier).
Which is more profitable, Incyte or Charles River Laboratories International?
Charles River Laboratories International is more profitable, with an operating margin of 20.6% against -45.5%.
More: Incyte earnings · how Incyte makes money · Charles River Laboratories International earnings · how Charles River Laboratories International makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.